Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
Recruiting · NCT07204275 · Registry updated 2026-09-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) | Primary Membranous Nephropathy | Recruiting | Phase 2 / Phase 3 | 2026-09-18 | NCT07204275 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Vertex Pharmaceuticals Incorporated | 37 |
| Zai Lab (Shanghai) Co., Ltd. (for China only) | 1 |
114 results · Page 1 of 5
Research sites
Swipe the table sideways for more columns.